Home › Trial NCT00250926
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
- Trial IDNCT00250926
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorDana-Farber Cancer Institute
- Enrollment23
- Start date2005-10
- ConditionsWaldenstrom's Macroglobulinemia
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.